

OssDsign Q4 - Delivering well in tough conditions

Redeye is encouraged to see OssDsign delivering well on sales (in line with our estimates), despite a continuously challenging market with restricted hospital access and still low elective surgery volumes. We believe 2023 should offer a better market outlook and increase our sales estimates for 2023e by 14%. We raise our fair value range following a review of Redeye Quality Rating, rendering a lower WACC than previously.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

OssDsign Q4 - Delivering well in tough conditions